Aquapheresis therapy, delivered by the Aquadex FlexFlow® System, uses a simplified approach to ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. Compared to renal replacement devices used for ultrafiltration, the Aquadex FlexFlow System is smaller and more portable.
Physicians can specify and adjust the exact amount and rate of fluid to be removed from each patient, resulting in a gradual reduction that has been shown to have no significant clinical impact on blood pressure, heart rate, or the balance of electrolytes (e.g. sodium, potassium, etc.) in the body
Up to 500 mL per hour of excess fluid can be removed with no clinically significant impact on electrolyte balance.
The Aquadex FlexFlow® System is an FDA cleared system designed to simply, safely, and precisely remove excess fluid (primarily excess salt and water) from patients suffering from fluid overload who have failed diuretic therapy. With the Aquadex FlexFlow, medical practitioners can specify and control the amount of fluid to be extracted at a safe, predictable, and effective rate with the option of hematocrit monitoring. The Aquadex FlexFlow has been shown to have no clinically significant impact on electrolyte balance, blood pressure or heart rate
The Aquadex FlexFlow offers a precise and safe approach to treating fluid overload:
Indication: The Aquadex FlexFlow System is indicated for temporary (up to 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy; and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies.